Albireo Pharma, Inc.: Italian Medicines Agency Approves Reimbursed Access to Bylvay (odevixibat) For Patients with All PFIC Types

Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that affects

Related Keywords

Germany ,Italy ,Boston ,Massachusetts ,United States ,United Kingdom ,Northern Ireland ,Craigavon ,Scotland ,Italian ,Colleen Alabiso ,Lorenzo Dantiga ,Lance Buckley ,Francesca Lombardozzi ,Hans Vitzthum ,Giuseppe Maggiore ,Thomas Topini ,Exchange Commission ,Albireo Pharma Inc ,Lifesci Advisors ,Italia Network ,Division Of Hepatology ,Italian Medicines Agency ,Nasdaq ,Positive Agenzia Italiana Del Farmaco ,Agenzia Italiana Del Farmaco ,Lorenzod Antiga ,Pediatric Transplantation ,Papa Giovanni ,Digestive Endoscopy ,Pediatric Hospital Bambino Ges ,Healthcare Provider General Inquires ,General Manager ,Test Abnormalities ,Soluble Vitamin ,Private Securities Litigation Reform Act ,Annual Report ,Albireo ,Dharma ,Medicines ,Agency ,Pproves ,Reimbursed ,Access ,Bylvay ,Odevixibat ,Patients ,Fific ,Types ,